Karuna Therapeutics Overview
- Year Founded
-
2009
- Status
-
Acquired/Merged
- Employees
-
210
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$13.8B
Karuna Therapeutics General Information
Description
Developer of a drug discovery platform intended to create and deliver transformative medicines for people living with psychiatric and neurological conditions. The company offers drug development capabilities for neurological and neuropsychiatric diseases, enabling the development of novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs.
Contact Information
Website
www.karunatx.comCorporate Office
- 99 High Street
- Floor 26
- Boston, MA 02110
- United States
Corporate Office
- 99 High Street
- Floor 26
- Boston, MA 02110
- United States
Karuna Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Merger/Acquisition | 18-Mar-2024 | $13.8B | Completed | Generating Revenue | ||
| 9. 2PO | 24-Mar-2023 | Completed | Generating Revenue | |||
| 8. 2PO | 11-Aug-2022 | Completed | Generating Revenue | |||
| 7. Secondary Transaction - Open Market | 26-Aug-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. IPO | 28-Jun-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 01-Apr-2019 | Completed | Clinical Trials - Phase 2 | |||
| 4. Later Stage VC (Series A) | 02-Aug-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Grant | 19-Jun-2018 | Completed | Clinical Trials - Phase 1 | |||
| 2. Accelerator/Incubator | 25-May-2011 | $244K | $244K | Completed | Startup | |
| 1. Accelerator/Incubator | 25-May-2011 | Completed | Startup |
Karuna Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 4,412,500 | $0.000100 | $1 | $1 | 1x | $1 | 27.84% |
Karuna Therapeutics Comparisons
Industry
Financing
Details
Karuna Therapeutics Competitors (49)
One of Karuna Therapeutics’s 49 competitors is Cerecin, a Venture Capital-Backed company based in Broomfield, CO.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Verge Labs | Venture Capital-Backed | San Francisco, CA | ||||
| MycoMedica Life Sciences | Venture Capital-Backed | Shelton, WA | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Praxis (Drug Discovery) | Formerly VC-backed | Boston, MA |
Karuna Therapeutics Patents
Karuna Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026072610-A1 | Process for preparing 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine l-(+)-tartrate | Pending | 25-Sep-2024 | ||
| WO-2026072607-A1 | Process for preparing 3-chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole | Pending | 25-Sep-2024 | ||
| WO-2026064593-A1 | Method and compositions relating to the treatment of neuro-degenerative and psychiatric diseases | Pending | 20-Sep-2024 | ||
| WO-2025255488-A2 | Xanomeline quercetin complexes and trospium salts | Pending | 06-Jun-2024 | ||
| WO-2025255488-A3 | Xanomeline quercetin complexes and trospium salts | Pending | 06-Jun-2024 | C07D417/04 |
Karuna Therapeutics Signals
Karuna Therapeutics Former Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ARCH Venture Partners | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| CONNECT (San Diego) | Accelerator/Incubator | Minority | ||
| Eventide Asset Management | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority |
Karuna Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
18.45 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Karuna Therapeutics FAQs
-
When was Karuna Therapeutics founded?
Karuna Therapeutics was founded in 2009.
-
Where is Karuna Therapeutics headquartered?
Karuna Therapeutics is headquartered in Boston, MA.
-
What is the size of Karuna Therapeutics?
Karuna Therapeutics has 210 total employees.
-
What industry is Karuna Therapeutics in?
Karuna Therapeutics’s primary industry is Drug Discovery.
-
Is Karuna Therapeutics a private or public company?
Karuna Therapeutics is a Private company.
-
What is the current valuation of Karuna Therapeutics?
The current valuation of Karuna Therapeutics is .
-
What is Karuna Therapeutics’s current revenue?
The current revenue for Karuna Therapeutics is .
-
How much funding has Karuna Therapeutics raised over time?
Karuna Therapeutics has raised $975M.
-
Who are Karuna Therapeutics’s investors?
ARCH Venture Partners, Alexandria Venture Investments, CONNECT (San Diego), Eventide Asset Management, and Fidelity Management & Research Company are 5 of 13 investors who have invested in Karuna Therapeutics.
-
Who are Karuna Therapeutics’s competitors?
Cerecin, Verge Labs, MycoMedica Life Sciences, Alzheon, and Praxis (Drug Discovery) are some of the 49 competitors of Karuna Therapeutics.
-
When was Karuna Therapeutics acquired?
Karuna Therapeutics was acquired on 18-Mar-2024.
-
Who acquired Karuna Therapeutics?
Karuna Therapeutics was acquired by Bristol-Myers Squibb.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process